Covid-19 vaccines administered here will not alter a person's genetic make-up and are safe, said an expert panel, as it urged people to get jabbed, given the importance of the vaccination drive in addressing Singapore's pandemic situation.. Read more at straitstimes.com.
Coronavirus | Plan to accelerate vaccine drive
Updated:
Updated:
Centre proposes additional vaccination sites, walk-in vaccinations
Share Article
AAA
A medical worker (L) inoculates a frontline staff with a Covid-19 vaccine at KIMS hospital in Hyderabad on January 25, 2021. (Photo by NOAH SEELAM / AFP)
| Photo Credit: AFP
Centre proposes additional vaccination sites, walk-in vaccinations
The Central government is all set to accelerate the first phase of COVID-19 vaccination drive by roping in additional vaccination sites and allowing walk-in vaccinations for those from the same group who have been registered in the CoWIN system.
Speaking to
The Hindu on Monday, V.K. Paul, Member (Health), NITI Aayog, and head of The National Expert Group on Vaccination (NEGVAC), said the next few weeks would see the government working at speeding up the coverage for the priority group.
Not at the cost of safety: We need innovative ways to beat the crisis
India
Published: Saturday, January 16, 2021, 13:00 [IST]
New Delhi, Jan 16: A Tropical Medicine Specialist, and an astute researcher with many noteworthy contributions in the field of Public Health, Dr Samiran Panda, Head, Epidemiology & Communicable Diseases Division, Indian Council of Medical Research and director, ICMR - National AIDS Research Institute talks about various aspects of vaccine development, vaccine safety and efficacy, and why India needs a vaccine to end the pandemic.
Dr Samiran Panda
In such a crisis, scientists and regulatory authorities have to be innovative and find faster ways of assessment of a vaccine but certainly not at the cost of safety.
Coronavirus | We are dealing with a virus which is easily transmissible and leaves a devastating effect, says ICMR scientist
Updated:
Updated:
January 15, 2021 21:53 IST
Scientists and regulatory authorities have to be innovative and find faster ways of vaccine assessment but not at the cost of safety, says ICMR’s Samiran Panda
Share Article
AAA
Dr Samiran Panda, Head of Epidemiology & Communicable Diseases Division with the Indian Council of Medical Research.
Scientists and regulatory authorities have to be innovative and find faster ways of vaccine assessment but not at the cost of safety, says ICMR’s Samiran Panda
As India begins one of the world’s largest COVID vaccination drives, Dr Samiran Panda, Head of Epidemiology & Communicable Diseases Division with the Indian Council of Medical Research – National AIDS Research Institute underlines the various stages of vaccine development adding that a March 2019 amendment in rules for new drugs and clinical tria
Updated Jan 13, 2021 | 19:51 IST
Dr Samiran Panda, Scientist G & Head of ECD division, ICMR, urged people to have an open mind and support the vaccination programme, adding that any vaccination can come with minor side-effects. Dr Samiran Panda, Head of ECD division, ICMR | Photo Credit: ANI
New Delhi: Amid criticism by Opposition for early approval for emergency use of Covaxin, Indian Council of Medical Research (ICMR) scientist Dr Samiran Panda has said that Bharat Biotech’s vaccine produces a wide range of antigens that will address the coronavirus mutants as well.
“The vaccine that India has developed (Covaxin) presents to the immune system a wide array of antigens, so the immunity which will be produced after vaccination is expected to address the mutants as well,” Dr Samiran Panda, Scientist G & Head of Epidemiology & Communicable Diseases Division division, ICMR, said.